Memantina Pentafarma

Memantine Hydrochloride, the active ingredient in Memantina Pentafarma, is an NMDA receptor antagonist presented as an oral tablet for oral use. It is used to manage symptoms of Alzheimer’s disease in adults, helping to preserve cognition and functional abilities.

GNH USA supplies Memantina Pentafarma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantina Pentafarma, a NMDA receptor antagonist, is indicated for the treatment of Alzheimer’s disease.

- Alzheimer’s disease (mild to moderate): helps maintain cognitive function and daily living activities. - Alzheimer’s disease (moderate to severe): reduces progression of symptoms and supports functional independence. - Behavioral disturbances in Alzheimer’s disease: may lessen agitation and aggression.

Memantina Pentafarma may cause a range of adverse reactions. Most are mild and reversible, while others are serious and require prompt medical attention.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Nausea: occasional upset stomach.

Serious or Rare Side Effects: - Seizures: rare convulsive episodes. - Hallucinations: visual or auditory disturbances. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Cardiac arrhythmia: irregular heart rhythm. - Stevens‑Johnson syndrome: severe skin reaction. - Elevated liver enzymes: possible hepatic involvement.

When prescribing Memantina Pentafarma, clinicians should consider several safety aspects.

- Renal impairment: assess kidney function and adjust dosing if needed. - Hepatic dysfunction: monitor liver enzymes periodically. - History of seizures: use with caution and observe for neurological changes. - Concomitant CNS depressants: evaluate for additive sedation. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture and direct sunlight.

Memantina Pentafarma can interact with other medicines, influencing its safety and efficacy.

Major Interactions (Avoid): - Amantadine: increased risk of neurotoxicity. - Ketamine: additive NMDA antagonism leading to excessive CNS depression. - High‑dose NMDA antagonists: may amplify central nervous system effects.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may worsen cognitive impairment. - Diuretics: can increase the likelihood of dizziness. - Alcohol: may enhance sedation and dizziness. - Certain anticonvulsants: may alter memantine plasma levels.